Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

May 21, 2024

BUY
$1.81 - $3.89 $1,133 - $2,435
626 Added 97.36%
1,269 $2,000
Q3 2023

Oct 30, 2023

BUY
$1.81 - $3.89 $1,133 - $2,435
626 Added 97.36%
1,269 $2,000
Q2 2023

May 21, 2024

SELL
$2.75 - $3.77 $60 - $82
-22 Reduced 3.31%
643 $1,000
Q2 2023

Jul 27, 2023

SELL
$2.75 - $3.77 $60 - $82
-22 Reduced 3.31%
643 $2,000
Q1 2023

May 21, 2024

BUY
$3.1 - $9.02 $520 - $1,515
168 Added 33.8%
665 $2,000
Q1 2023

Apr 27, 2023

BUY
$3.1 - $9.02 $520 - $1,515
168 Added 33.8%
665 $2,000
Q4 2022

May 21, 2024

BUY
$5.42 - $10.24 $2,693 - $5,089
497 New
497 $2,000
Q4 2022

Jan 31, 2023

BUY
$5.42 - $10.24 $211 - $399
39 Added 8.52%
497 $3,000
Q3 2022

Oct 21, 2022

BUY
$8.03 - $12.77 $3,677 - $5,848
458 New
458 $4,000

Others Institutions Holding CCCC

About C4 Therapeutics, Inc.


  • Ticker CCCC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,913,800
  • Market Cap $208M
  • Description
  • C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...
More about CCCC
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.